Reg. Office: 28, Level 1, am @ 10, MB Towers, H No. 8-2-624/A/1, Road No.

10, Banjara Hills, Hyderabad 500034, Telangana

Corp Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai 400053
Email ID: rubraltd@gmail.com | Website: www.rubramed.com
CIN: L33100TG1991PLC013266 | Tel: +91 9167469649

November 10, 2016

To,
BSE Limited,
P. J. Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 531099
Sub: Outcome of Board Meeting
Re: Un-audited Financial Results for the Quarter and half year ended September 30, 2016
Dear Sir(s),
With reference to the captioned subject, please find enclosed herewith, the Un-audited Financial
Results of the Company for the Quarter and half year ended September 30, 2016 which was
approved by the Board of Directors in their meeting held today i.e. November 10, 2016.
Also attach is Limited Review Report for the quarter and half year ended on September 30, 2016
given by the Statutory Auditor of the Company.
You are requested to make note of the same.
Thanking you,
Yours faithfully,
For Rubra Medicaments Limited

AbhaKapoor
Director (Finance) and Chief Financial Officer
DIN 02799429

RUBRA MEDICAMENTS LIMITED

Part I
Sr.
No

2
a
b
c
d
e
f

3
4
5
6
7

(Rupees in Lacs)
Statement of Standalone Un-audited Results for the Quarter ended September 30, 2016
3 months ended
Preceeding 3
Corresponding 3 Year to date
Particulars
months ended

Income from operations

Net Sales/Income form Operations (Net of Excise Duty)
Other Operating Income
Total Income from Operations (Net)
Expenses
Cost of Materials Consumed
Purchases of Stock-in-trade
Changes in Inventories of fininshed goods, work-in-progress and
stock-in-trade
Employee Benefit Expense
Depreciation and amortisation expenses
Other Expenses (Any item exceeding 10% of the total expenses
relating to continuing operatons to be shown separately)

Year to date
months ended in figures for current figures for
previous year
period ended
pervious period
ended

Current Year
Ended

30-Sep-2016

30-Jun-2016

30-Sep-2015

30-Sep-2016

30-Sep-2015

31-Mar-16

Unaudited

Unaudited

Unaudited

Unaudited

Unaudited

Audited

7.88
0.00
7.88

7.25
0.00
7.25

6.12
0.00
6.12

15.13
0.00
15.13

6.12
0.00
6.12

19.54
0.00
19.54

0.00
4.36
0.00

0.00
3.57
0.00

0.00
2.06
0.00

0.00
7.93
0.00

0.00
2.06
0.00

0.00
12.59
0.00

0.45
0.01
2.03

0.45
0.00
2.76

0.45
0.00
3.44

0.90
0.01
4.79

0.90
0.00
4.36

1.80
0.00
5.83

Total Expenses
Profit / (Loss) from operations before other income, finance
costs and exceptional items (1-2)

6.85
1.02

6.78
0.47

5.95
0.17

13.63
1.49

7.32
-1.20

20.22
-0.68

Other Income
Profit / (Loss) from Ordinary activities before finance costs
and exceptional items (3+4)
Finance Cost

0.00
1.02

0.00
0.47

0.00
0.17

0.00
1.49

0.00
-1.20

0.00
-0.68

0.00
1.02

0.00
0.47

0.00
0.17

0.00
1.49

0.00
-1.20

0.00
-0.68

0.00
1.02
0.00
1.02
0.00
1.02
0.00
0.00
1.02

0.00
0.47
0.00
0.47
0.00
0.47
0.00
0.00
0.47

0.00
0.17
0.00
0.17
0.00
0.17
0.00
0.00
0.17

0.00
1.49
0.00
1.49
0.00
1.49
0.00
0.00
1.49

0.00
-1.20
0.00
-1.20
0.00
-1.20
0.00
0.00
-1.20

0.00
-0.68
0.00
-0.68
0.00
-0.68
0.00
0.00
-0.68

546.83

546.83

546.83

546.83

546.83

546.83

0.02
0.02

0.01
0.01

0.00
0.00

0.03
0.03

-0.02
-0.02

-0.01
-0.01

0.02
0.02

0.01
0.01

0.00
0.00

0.03
0.03

-0.02
-0.02

-0.01
-0.01

Profit / (Loss) from Ordinary activities after finance costs but

before exceptional items (5+6)
8 Exceptional Items
9 Profit / (Loss) from Ordinary activities before tax (7+8)
10 Tax Expenses
11 Profit / (Loss) from Ordinary activities after tax (9+10)
12 Extraordinary Items (net of tax expense)
13 Net Profit / (Loss) for the period (11+12)
14 Share of Profit/(Loss) of associates
15 Minority Interest
16 Net Profit / (Loss) after taxes, minority interest and share of profit
/(loss) of associates (13+14+15)
17 Paid-up equity share capital (Face value of the Share is Rs.10/each)
18 Reserves excluding Revaluation Reserves as per balance sheet) of
previous accounting year
19.i Earnings Per Share (EPS) (before Extraordinary items) of Rs. 10/each (not to be annualized)
a) Basic
b) Diluted
19.ii Earnings Per Share (EPS) (after Extraordinary items) of Rs. 10/(not to be annualized)
a) Basic
b) Diluted

Notes:
The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today

The Segment-wise details are not applicable to the company as company has no segments.

The result is provisional and unaudited and subject to change regrouping and restatement

The results are Ind-AS compliant however, the previous years figures are not subject to limit review or audit. However, the management has exercised
necessary due diligence to ensure that the Financial Results provide a true and fair view of its affairs.
Date: November 10, 2016
Place: Mumbai
Abha Kapoor
Director (Finance) and CFO

RUBRAMEDICAMENTSLIMITED
A
1

STATEMENTOFASSETSANDLIABILITIES
As on September 30,
EQUITYANDLIABILITIES
2016
ShareholdersFunds
(a)
ShareCapital
54,683,000
(b) ReservesandSurplus
(50,693,456)
(c) Moneyreceivedagainstsharewarrants
SubtotalShareholders'funds
3,989,544

As on March 31,
2016
54,683,000
(50,842,784)
3,840,216

2 Shareapplicationmoneypendingallotment

3 Minorityinterest

4 Noncurrentliabilities
(a)
Longtermborrowings
(b) Deferredtaxliabilities(net)
(c) Otherlongtermliabilities
(d) Longtermprovisions
SubtotalNoncurrentliabilities

746,257

746,257

746,257

746,257

5 Currentliabilities
(a)
Shorttermborrowings
(b) Tradepayables
(c) Othercurrentliabilities
(d) Shorttermprovisions
SubtotalCurrentliabilities

75,000



75,000

4,810,801

4,586,473

ASSETS
B
1 Noncurrentassets
(a)
Fixedassets
(b) Goodwillonconsolidation
(c)
Noncurrentinvestments
(d) Deferredtaxassets(net)
(e) Longtermloansandadvances
(f)
Othernoncurrentassets
SubtotalNoncurrentassets

9,789



3,369,070
168,819
3,547,678

3,282,070
168,819
3,450,889

2 CurrentAssets
(a)
Currentinvestments
(b) Inventories
(c)
Tradereceivables
(d) Cashandcashequivalents
(e) Shorttermloansandadvances
(f)
Othercurrentassets
SubtotalCurrentassets
TOTALASSETS

177,269
1,085,854


1,263,123
4,810,801

177,269
958,315

1,135,584
4,586,473

TOTALEQUITYANDLIABILITIES

Prakash Modi & Associates

Chartered

Accountants

A-305, DurianEstate,Goregaon
MulundLinkRoad,Goregaon
(E),Mumbai400063. T: 93244 76022 E: mandpca@gmail.com
W: www.capmassociates.com

Limited Review Report of the Auditors

To,
The Board of Directors
Rubra Medicaments Limited
Hyderabad
Sub: limited Review Report
We have reviewed the accompanying statement of unaudited financial results of Rubra
Medicaments Limited for the period ended September 30, 2016. This statement is the responsibility
of the Company's Management and has been approved by the Board of Directors. Our responsibility
is to issue a report on these financial statements based on our review.
We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400,
Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of
India. This standard requires that we plan and perform the review to obtain moderate assurance as
to whether the financial statements are free of material misstatement. A review is limited primarily
to inquiries of company personnel and analytical procedures applied to financial data and thus
provides less assurance than an audit. We have not performed an audit and accordingly, we do not
express an audit opinion.
Based on our review conducted as above, nothing has come to our attention that causes us to
believe that the accompanying statement of unaudited financial results prepared in accordance with
applicable accounting standards and other recognized accounting practices and policies has not
disclosed the information required to be disclosed interms of Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 includingthe manner in which it is to be
disclosed, or that it contains any material misstatement.

For Prakash Modi & Associates

Chartered Accountants
FRN: 116900W

- ..
,.; ~':
-

,-''

I' ~,-:::.

""'1-

0\o.~.
\L~ , \
."'",-

vI

PrakashModi
Partner
M No. 101463

~,

..

~.

.
'.

.:'-

Place: Mumbai
Date: 'November 10, 2016

411/412IndraprasthaIIC, Jttendra Road, Malad(East), Mumbai 400 097.